Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
Status:
Completed
Trial end date:
2006-07-17
Target enrollment:
Participant gender:
Summary
Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic
activity) in the treatment of schizophrenia.
The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is
superior to placebo in the treatment of patients with schizophrenia as measured by the
Positive and Negative Symptom Scales (PANSS) total score.